New study below [1].
PCa is perhaps a unique disease, in that treatment largely depends on whether the patient first sees a urologist or oncologist. As recent as 2014 (U.S.):
"Radiation oncologists and urologists both prefer the treatment modalities they offer, perceive them to be more effective and to lead to a better QOL. Patients may be receiving biased information, and a truly informed consent process with shared decision-making may be possible only if they are evaluated by both specialties before deciding upon a treatment course." [2]
& August (Australia):
"Radiation oncologists were more likely to recommend adjuvant RT and consider it to be underutilized, and more likely to recommend salvage RT at lower prostate-specific antigen thresholds ... Urologists were more likely to recommend salvage radical prostatectomy or cryoablation for local salvage after RT, whereas radiation oncologists were more likely to recommend RT-based modalities and more likely to report that local salvage was underutilized after RT ... Urologists were more likely to report that upfront radical prostatectomy was a better definitive treatment .., whereas radiation oncologists were more likely to report the opposite ..." [3]
"A plague o' both your houses" Shakespeare
Every now & then, an oncologist will publicly insist that RP is not the gold standard. Only to be followed by a study that shows that it remains so.
In the new study:
"Population-based data indicated that patients with prostate cancer who received treatment with either surgery or radiotherapy had improved overall survival compared with a cohort of matched noncancer controls."
"Surgery produce longer survival compared with radiation therapy."
So far, so good. But then comes the interpretation bias:
"These results suggest an inherent selection-bias because of unmeasured confounding variables."
In other words, if it wasn't for selection bias, RP would not have won.
Since we know that there is selection bias, based on the specialist one sees, the selection is essentially random for many men. An ideal basis for a comparative study.
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/280...
Cancer. 2017 Jan 18. doi: 10.1002/cncr.30506. [Epub ahead of print]
Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data.
Williams SB1, Huo J2, Chamie K3, Smaldone MC4, Kosarek CD1, Fang JE1, Ynalvez LM1, Kim SP5, Hoffman KE6, Giordano SH2,7, Chapin BF8.
Author information
1Division of Urology, The University of Texas Medical Branch, Galveston, Texas.
2Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
3Department of Urology, University of California-Los Angeles, Los Angeles, California.
4Department of Urology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania.
5Department of Urology, Case Western Reserve University, Cleveland, Ohio.
6Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
7Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
8Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND:
The objective of this study was to compare the overall survival of patients who undergo radical prostatectomy or radiotherapy versus noncancer controls to discern whether there is a survival advantage according to prostate cancer treatment and the impact of selection bias on these results.
METHODS:
A matched cohort study was performed using the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. In total, 34,473 patients ages 66 to 75 years were identified who were without significant comorbidity, were diagnosed with localized prostate cancer, and received treatment treated with surgery or radiotherapy between 2004 and 2011. These patients were matched to a noncancer control cohort. The rates of all-cause mortality that occurred within the study period were compared. Cox proportional hazards regression analysis was used to identify determinants associated with overall survival.
RESULTS:
Of 34,473 patients who were included in the analysis, 21,740 (63%) received radiation therapy, and 12,733 (37%) underwent surgery. There was improved survival in patients who underwent surgery (hazard ratio, 0.35; 95% confidence interval, 0.32-0.38) and in those who received radiotherapy (hazard ratio, 0.72; 95% confidence interval, 0.68-0.75) compared with noncancer controls. Overall survival improved significantly in both treatment groups, with the greatest benefit observed among patients who underwent surgery (log rank P < .001).
CONCLUSIONS:
Population-based data indicated that patients with prostate cancer who received treatment with either surgery or radiotherapy had improved overall survival compared with a cohort of matched noncancer controls. Surgery produce longer survival compared with radiation therapy. These results suggest an inherent selection-bias because of unmeasured confounding variables. Cancer 2017. © 2017 American Cancer Society.
© 2017 American Cancer Society.
KEYWORDS:
outcomes; prostate cancer; prostatectomy; survival; treatments; utilization
PMID: 28099688 DOI: 10.1002/cncr.30506